{
    "code": "02024617",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02024617",
    "time": "2020-12-18 03:11:21",
    "許可證字號": "衛署藥輸字第024617號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "111\/02\/08",
    "發證日期": "96\/02\/08",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA00202461701",
    "中文品名": "依瑞諾丁濃縮注射液",
    "英文品名": "Irinotecan Injection Concentrate",
    "適應症": "晚期性大腸直腸癌之第一線治療藥物： 與5-FU及folinic acid合併，使用於未曾接受過化學治療之患者。 單獨使用於曾接受5-FU療程治療無效之患者。 與cetuximab併用，治療曾接受含irinotecan之細胞毒性療法治療失敗且具有上皮生長因子接受體(EGFR)表現型KRAS野生型轉移性大腸直腸癌患者。 與5-fluorouracil、folinic acid及bevacizumab合併治療，做為轉移性大腸癌或直腸癌患者的第一線治療藥物。 與capecitabine合併治療，做為轉移性大腸直腸癌患者的第一線治療藥物。",
    "劑型": "270注射劑",
    "包裝": "2毫升、5毫升小瓶 100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "",
    "主成分略述": "IRINOTECAN HYDROCHLORIDE TRIHYDRATE",
    "限制項目": "02輸　入 25監視中學名藥",
    "申請商名稱": "1504401100  輝瑞大藥廠股份有限公司",
    "申請商地址": "台北市信義區松仁路100號42、43樓",
    "主製造廠": [
        {
            "製造廠名稱": "FIN0567000  ZYDUS HOSPIRA ONCOLOGY PRIVATE LIMITED",
            "製造廠廠址": "PHARMEZ SPECIAL ECONOMIC ZONE, PLOT NO.3, SARKHEJ-BAVLA ROAD, N.H. NO. 8A, VILLAGE: MATODA, TALUKA: SANAND, DISTRICT-AHMEDABAD-382 213 (GUJARAT), INDIA",
            "製造廠公司地址": "",
            "製造廠國別": "INDIA",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "6605071926  久裕企業股份有限公司",
            "製造廠廠址": "桃園市桃園區大林里興邦路43巷2之1號4樓，3樓B區，1樓A區",
            "製造廠公司地址": "",
            "製造廠國別": "",
            "製程": "二級包裝廠(委託貼標及置入仿單)"
        }
    ],
    "CCC號列": "30049071005 抗癌藥Anti-cancer preparations",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "9200037710",
            "成分名稱": "IRINOTECAN HYDROCHLORIDE TRIHYDRATE",
            "含量描述": "",
            "含量": "20.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "HSP Irinotecan LLD MOH20190416-3 (MOH 20190626)-109-06-04(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02024617&Seq=017&Type=9"
        },
        {
            "title": "Irinotecan-license 024617-081023-108-11-22.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02024617&Seq=016&Type=9"
        },
        {
            "title": "024617 Hospira Irinitecan product photo-109-06-04(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02024617&Seq=017&Type=8"
        },
        {
            "title": "024617 Hospira Irinitecan product photo-108-07-11(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02024617&Seq=016&Type=8"
        },
        {
            "title": "HSP irinotecan injection products photos-108-07-05(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02024617&Seq=015&Type=8"
        },
        {
            "title": "Irino_AU pack_6面+瓶身-106-06-20(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02024617&Seq=014&Type=8"
        },
        {
            "title": "024617 外盒及標籤-106-04-10.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02024617&Seq=013&Type=8"
        }
    ]
}